Ablation as First-Line Therapy for Atrial Fibrillation: Yes

Cardiac Electrophysiology Clinics

Volumn 4, Issue 3, 2012, Pages 287-297

  Santangeli, Pasquale ^a,b   Di Biase, Luigi ^a,b   Al Ahmad, Amin ^c   Horton, Rodney ^a   Burkhardt, J David ^a   Sanchez, Javier E ^a   Gallinghouse, G Joseph ^a   Zagrodzky, Jason ^a   Bai, Rong ^a,d   Pump, Agnes ^a,e   Mohanty, Sanghamitra ^a   Lewis, William R ^f   Natale, Andrea ^a,c,f,g,h  

^a TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^b UNIVERSITY OF FOGGIA   (Italy)

^c STANFORD UNIVERSITY   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNIVERSITY OF PÉCS   (Hungary)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SCRIPPS CLINIC   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Catheter ablation; First line therapy

Indexed keywords

AMIODARONE; CARDIAC AGENT; SODIUM CHANNEL BLOCKING AGENT;

ARTERIOVENOUS FISTULA; BLEEDING; BRADYCARDIA; CATHETER ABLATION; COST EFFECTIVENESS ANALYSIS; DEATH; ELDERLY CARE; GROIN HEMATOMA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PULMONARY VEIN OBSTRUCTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84865555632     PISSN: 18779182     EISSN: 18779190     Source Type: Journal    
DOI: 10.1016/j.ccep.2012.05.011     Document Type: Review

References (57)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285(18):2370-2375.
2. Friberg J., Buch P., Scharling H., et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003, 14(6):666-672.
3. Bialy D., Lehmann H., Schumacher D.N., et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol 1992, 19(3):41A. 41.
4. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98(10):946-952.
5. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
6. Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010, 303(4):333-340.
7. Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008, 118(24):2498-2505.
8. Calkins H., Reynolds M.R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009, 2(4):349-361.
9. Verma A., Natale A. Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients. Circulation 2005, 112(8):1214-1222. [discussion: 1231].
10. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005, 293(21):2634-2640.
11. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109(12):1509-1513.
12. Pedersen O.D., Brendorp B., Elming H., et al. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev 2003, 7(3):220-224.
13. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998, 98(23):2574-2579.
14. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347(23):1825-1833.
15. Hagens V.E., Ranchor A.V., Van Sonderen E., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004, 43(2):241-247.
16. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41(10):1690-1696.
17. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342(13):913-920.
18. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989, 321(6):406-412.
19. Waldo A.L., Camm A.J., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348(9019):7-12.
20. Padanilam B.J., Prystowsky E.N. Should atrial fibrillation ablation be considered first-line therapy for some patients? Should ablation be first-line therapy and for whom? The antagonist position. Circulation 2005, 112(8):1223-1229. [discussion: 1230].
21. Namdar M., Chierchia G.B., Westra S., et al. Isolating the pulmonary veins as first-line therapy in patients with lone paroxysmal atrial fibrillation using the Cryoballoon. Europace 2012, 14(2):197-203.
22. Nielsen J, Johannessen A, Raatikainen P, et al. A randomized multicenter comparison of radiofrequency ablation and antiarrhythmic drug therapy as first-line treatment in 294 patients with paroxysmal atrial fibrillation. Presented at the AHA 2011 Scientific Session (LBCT.03). Available at: . Accessed January 2012. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433720.pdf.
23. Tanner H., Makowski K., Roten L., et al. Catheter ablation of atrial fibrillation as first-line therapy-a single-centre experience. Europace 2011, 13(5):646-653.
24. First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT-2 Study). NCT00392054. Available at: . http://clinicaltrials.gov/ct2/show/NCT00392054.
25. Jons C., Hansen P.S., Johannessen A., et al. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. Europace 2009, 11(7):917-923.
26. Khaykin Y., Skanes A., Champagne J., et al. A randomized controlled trial of the efficacy and safety of electroanatomic circumferential pulmonary vein ablation supplemented by ablation of complex fractionated atrial electrograms versus potential-guided pulmonary vein antrum isolation guided by intracardiac ultrasound. Circ Arrhythm Electrophysiol 2009, 2(5):481-487.
27. Tamborero D., Mont L., Berruezo A., et al. Circumferential pulmonary vein ablation: does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm 2010, 7(5):612-618.
28. Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006, 27(2):216-221.
29. Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006, 48(11):2340-2347.
30. Krittayaphong R., Raungrattanaamporn O., Bhuripanyo K., et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 2003, 86(Suppl 1):S8-S16.
31. Santangeli P., Di Biase L., Sanchez J.E., et al. Atrial fibrillation ablation without interruption of anticoagulation. Cardiol Res Pract 2011, 2011:837841.
32. Di Biase L., Burkhardt J.D., Mohanty P., et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010, 121(23):2550-2556.
33. Santangeli P., Di Biase L., Pelargonio G., et al. Catheter ablation of atrial fibrillation: randomized controlled trials and registries, a look back and the view forward. J Interv Card Electrophysiol 2011, 31(1):69-80.
34. Lee G., Sparks P.B., Morton J.B., et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011, 22(2):163-168.
35. Leong-Sit P., Zado E., Callans D.J., et al. Efficacy and risk of atrial fibrillation ablation before 45 years of age. Circ Arrhythm Electrophysiol 2010, 3(5):452-457.
36. Khaykin Y., Wang X., Natale A., et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009, 20(1):7-12.
37. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006, 27(8):949-953.
38. Kopecky S.L., Gersh B.J., McGoon M.D., et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987, 317(11):669-674.
39. Zado E., Callans D.J., Riley M., et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2008, 19(6):621-626.
40. Corrado A., Patel D., Riedlbauchova L., et al. Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians. J Cardiovasc Electrophysiol 2008, 19(8):807-811.
41. Santangeli P., Biase L.D., Mohanty P., et al. Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. J Cardiovasc Electrophysiol 2012, [Epub ahead of print].
42. Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006, 354(9):934-941.
43. Flaker G.C., Blackshear J.L., McBride R., et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992, 20(3):527-532.
44. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996, 28(6):1458-1463.
45. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341(12):857-865.
46. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995, 333(2):77-82.
47. Nul D.R., Doval H.C., Grancelli H.O., et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina. J Am Coll Cardiol 1997, 29(6):1199-1205.
48. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997, 350(9089):1417-1424.
49. Chen M.S., Marrouche N.F., Khaykin Y., et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004, 43(6):1004-1009.
50. Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351(23):2373-2383.
51. Gentlesk P.J., Sauer W.H., Gerstenfeld E.P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18(1):9-14.
52. Efremidis M., Sideris A., Xydonas S., et al. Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling. Hellenic J Cardiol 2008, 49(1):19-25.
53. Lutomsky B.A., Rostock T., Koops A., et al. Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace 2008, 10(5):593-599.
54. Khan M.N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008, 359(17):1778-1785.
55. De Potter T., Berruezo A., Mont L., et al. Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace 2010, 12(1):24-29.
56. Choi A.D., Hematpour K., Kukin M., et al. Ablation vs medical therapy in the setting of symptomatic atrial fibrillation and left ventricular dysfunction. Congest Heart Fail 2010, 16(1):10-14.
57. MacDonald M.R., Connelly D.T., Hawkins N.M., et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011, 97(9):740-747.